This episode features Dr. Alexander Olawaiye, discussing major advances in ovarian cancer treatment, including the ROSELLA clinical trial.
 
 Key Highlights:
1. Ovarian Cancer Challenges:
- No reliable early screening methods
- Majority diagnosed at advanced stages (Stage III/IV)
- Early detection remains a critical unmet need

2. ROSELLA Trial Breakthrough:
- Focus on platinum-resistant ovarian cancer
- Combines relacorilant (a glucocorticoid receptor antagonist) with nab-paclitaxel
- Demonstrated improved progression-free survival and overall survival
- No biomarker requirement, making it accessible to more patients

3. Mechanism of Action:
- Relacorilant blocks cortisol signaling that promotes chemotherapy resistance
- Enhances effectiveness of chemotherapy

4. Safety & Tolerability:
- No new major toxicities identified
- Side effects consistent with standard chemotherapy

5. Clinical Trial Importance:
- Patients in trials often experience better outcomes
- Participation helps advance future treatments

6. Health Equity & Access:
- Disparities exist in access to care and clinical trials
- Need to improve awareness, access, and inclusion

7. Future Outlook:
- Rapid growth in new treatments over past decade
- Emerging therapies include antibody-drug conjugates
- Continued innovation offers hope for patients

 Closing Message:
Stay informed, consider clinical trials, and remain hopeful as new treatments continue to emerge.